Phase I/II study of a rheumatoid arthritis drug used in systemic sclerosis shows signs of efficacy and RNA technology is instrumental in the discovery
Nearly half of people over 50 say arthritis or joint pain limits their usual activities, but many haven’t talked to a doctor about medication risks.
The same metabolite is linked to cardiovascular and metabolic diseases.
The discovery could be a route to novel treatments for the autoimmune disease.
The findings could lead to repurposing drugs for patients with the sometimes-fatal condition.
In patients with lupus, immune cells undergo an inflammatory transformation when migrating from the blood to the skin.